SCI Pharmtech Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
SCI Pharmtech Fair Value Forecast for 2023 - 2025 - 2030
SCI Pharmtech's Price has decreased In the last four years, from NT$81.78 to NT$0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach NT$0.00 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1795 Stock Forecast | Lotus Pharmaceutical | Buy |
16
|
NT$314.50 | Buy/Sell | NT$339.40 | 9.38% |
| 6472 Stock Forecast | Bora Pharmaceuticals Co., LTD. | Outperform |
15
|
NT$752.00 | Buy/Sell | NT$703.67 | 13.03% |
| 4123 Stock Forecast | Center Laboratories | - |
10
|
NT$46.70 | Buy/Sell | NT$0.00 | -100.00% |
| 1789 Stock Forecast | ScinoPharm Taiwan | Hold |
18
|
NT$28.15 | Buy/Sell | NT$26.00 | -7.64% |
| 4105 Stock Forecast | TTY Biopharm Company | Hold |
18
|
NT$76.60 | Buy/Sell | NT$86.00 | 12.92% |
SCI Pharmtech Revenue Forecast for 2023 - 2025 - 2030
SCI Pharmtech's Revenue has decreased In the last two years, from NT$2.69B to NT$899.74M – a 66.54% drop. In the next year, analysts believe that Revenue will reach NT$1.51B – an increase of 67.76%. For the next eight years, the forecast is for Revenue to grow by 88.25%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6620 Stock Forecast | Handa Pharmaceuticals | Buy |
4
|
NT$130.50 | Buy/Sell | NT$200.00 | 53.26% |
| 8436 Stock Forecast | TCI | Hold |
16
|
NT$145.50 | Buy/Sell | NT$185.20 | 16.84% |
| 4114 Stock Forecast | Synmosa Biopharma | Hold |
14
|
NT$38.10 | Buy/Sell | NT$36.00 | -100.00% |
.jpg)
SCI Pharmtech Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, SCI Pharmtech's Dividend per Share has seen a drop from NT$0.42 to NT$0.22 – a 47.62% decrease. For the next year, analysts predict that Dividend per Share will reach NT$0.42 – an increase of 90.91%. Over the next eight years, experts believe that SCI Pharmtech's Dividend per Share will grow at a rate of 88.72%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6576 Stock Forecast | Foresee Pharmaceuticals | Buy |
6
|
NT$95.00 | Buy/Sell | NT$122.25 | 61.05% |
| 6586 Stock Forecast | CHO Pharma | - |
6
|
NT$55.20 | Buy/Sell | NT$0.00 | -100.00% |
| 3705 Stock Forecast | YungShin Global Holding | - |
18
|
NT$46.70 | Buy/Sell | NT$0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1760 Stock Forecast | Panion & Bf Biotech | - |
16
|
NT$96.50 | Buy/Sell | NT$102.00 | -100.00% |
| 1701 Stock Forecast | China Chemical & Pharmaceutica... | - |
16
|
NT$23.60 | Buy/Sell | NT$0.00 | -100.00% |
| 3266 Stock Forecast | Sunty Development Co., LTD | - |
15
|
NT$20.95 | Buy/Sell | NT$0.00 | -100.00% |
SCI Pharmtech EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, SCI Pharmtech's EBITDA has fallen from NT$1.18B to NT$207.95M – a 82.42% decrease. Analysts predict that SCI Pharmtech's EBITDA will increase in the upcoming year, reaching NT$695.08M. This would represent an increase of 234.25%. Over the next eight years, experts predict that SCI Pharmtech's EBITDA will grow at a rate of 492.76%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6575 Stock Forecast | SyneuRx International (Taiwan) | - |
9
|
NT$48.95 | Buy/Sell | NT$0.00 | -100.00% |
| 1734 Stock Forecast | Sinphar Pharmaceutical | - |
8
|
NT$36.65 | Buy/Sell | NT$24.00 | -100.00% |
| 6634 Stock Forecast | Sinew Pharma | - |
7
|
NT$57.80 | Buy/Sell | NT$0.00 | -100.00% |
SCI Pharmtech EBIT Forecast for 2023 - 2025 - 2030
In the last two years, SCI Pharmtech's EBIT has decreased from NT$1.05B to NT$118.97M – a 88.69% drop. In the next year, analysts believe that EBIT will reach NT$615.25M – an increase of 417.14%. For the next eight years, the forecast is forEBIT to grow by 1297.70%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6657 Stock Forecast | Energenesis Biomedical CO.,LTD... | - |
8
|
NT$54.80 | Buy/Sell | NT$0.00 | -100.00% |
| 4108 Stock Forecast | PhytoHealth | - |
4
|
NT$19.80 | Buy/Sell | NT$36.50 | -100.00% |
| 4166 Stock Forecast | Orient Pharma | - |
4
|
NT$20.55 | Buy/Sell | NT$0.00 | -100.00% |
SCI Pharmtech EPS Price Prediction Forecast for 2023 - 2025 - 2030
SCI Pharmtech's EPS has decreased In the last four years, from NT$3.36 to NT$0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach NT$0.00 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1752 Stock Forecast | Nang Kuang Pharmaceutical | - |
18
|
NT$48.40 | Buy/Sell | NT$0.00 | -100.00% |
| 6461 Stock Forecast | Intech Biopharm | - |
5
|
NT$30.80 | Buy/Sell | NT$0.00 | -100.00% |
| 1762 Stock Forecast | Chunghwa Chemical Synthesis & ... | Hold |
16
|
NT$44.90 | Buy/Sell | NT$70.00 | 6.90% |
.jpg)